CareDx, Inc. (CDNA) stock intrinsic value fair value estimate & owner earnings analysis

CareDx sells blood-based surveillance tests for organ-transplant patients (AlloSure for kidney and heart, AlloMap for heart) plus software and patient-services offerings, and has just reshaped itself: on June 30, 2026 it sold its Lab Products business to Eurobio Scientific for roughly $172 million in cash (a $113 million accounting gain), and the company has said it closed the acquisition of Naveris, a cancer-monitoring test maker. Reported terms are $160 million up front and up to $100 million more in milestones. We value the business that remains, plus its cash, less what it has committed to pay. What the business actually earns. After charging stock compensation as the real cost it is, and stripping out working-capital timing, the company has not produced positive owner earnings in any year from 2016 through 2025 once those adjustments are made. The figures are about -$33 million in 2024 (adjusted for the item below) and -$7 million (-$0.14 per share) in 2025. Cash from operations looks better (about $42 million in 2025) only because $34.9 million of pay was in shares (it was $66.4 million in 2024), and because of working-capital swings. Two items are removed as non-recurring: a $96.3 million litigation accrual booked in 2023 and reversed in 2024, and a $20.5 million government advance in 2020 that was repaid in 2021. The starting level we use is the 2024-2025 median, about -$0.37 per share. Recent results are stronger: second-quarter 2026 revenue rose 52% to $132 million and first-half operating cash flow was $34.9 million. However, $18.0 million of second-quarter revenue ($35.6 million for the half) was for tests performed in earlier periods, higher payer refund reserves took $5.8 million off the half, and stock compensation was $20.5 million for the half, so we do not move the earnings level on these results. Trailing owner earnings improved by roughly $26 million in 2025; we assume the first forward year is worse (about -$14 million) because Lab Products earnings are gone and stock compensation is running near $41 million a year. Cash and obligations. The company has no borrowings. It held $373.6 million of cash at June 30, 2026. We deduct the $160 million Naveris payment and set aside $50 million for operating needs, leaving about $164 million, or $3.06 per share on 53.4 million diluted shares. We give Naveris no earnings credit in any case: it has revenue (reported at about $34 million for 2025) and Medicare coverage, but nothing in the filings shows it earns money after stock pay, so we count only the cash outflow. Optional milestone payments are excluded. Base case, $3.71 per share. Business value about $35 million plus $164 million excess cash, no debt, equals $198 million. Owner earnings start at -$14 million and improve by about $3.4 million a year, reaching breakeven in the fifth year and about $17 million by year ten, then fade to zero over the following decade. The improvement rests on revenue growth near the 6% a year the company achieved from 2021 to 2025 and a modest drop-through of about 15% on added revenue, which sits within the 10% to 17% of added revenue that has reached cash earnings before stock pay since 2020 and 2021. We left out the 52% quarterly growth, margin targets, Naveris and any share gains, because none is yet reflected in owner earnings. Bear case, -$0.21 per share. Two named risks: (1) Natera has appealed the 2025 ruling that invalidated its patents; if it wins, CareDx faces the $96.3 million verdict plus interest, which we put near $105 million; (2) a repeat of 2022-2023, when revenue fell 13% (from $321.8 million to $280.3 million) and cash earnings before stock pay swung from about -$15 million to about -$34 million. We assume owner earnings of -$25 million for two years, then -$10 million for three, then zero, worth about -$70 million. Business value of -$70 million plus $164 million of excess cash, less $105 million, leaves roughly -$11 million: in this case the company appears to owe slightly more than it is worth. Bull case, $12.12 per share. Business value about $484 million plus $164 million of excess cash, no debt, equals $647 million. Revenue grows 10% a year for five years (below the 14% of 2025 and the 17% test-volume growth in the latest quarter), then 5%, with 20% of added revenue reaching owner earnings and stock compensation held flat, taking owner earnings from about -$1 million to about $85 million by year ten before fading to zero. What could make this wrong: stock compensation falling faster than assumed would lift every case; Naveris proving profitable after stock pay would add value we have excluded; a Natera appeal loss or a payer reimbursement reset would cut value. A $44.9 million award against Natera in CareDx's false-advertising case was affirmed and review was denied on June 1, 2026; we count no receipt because none has been recorded. The previous analysis was built on a different earnings basis and its figures are not comparable. Margin-of-safety price, $2.50. We are fairly sure of the cash, since the company has no borrowings, but not of the earnings: owner earnings have been negative for ten years and the cases range from slightly below zero to about $12. The worst plausible outcome is the bear case, where the Natera appeal and a reimbursement reset together consume most of the excess cash; the business has no debt and could survive that, but shareholders would be left with little. If we are wrong about stock pay staying near $40 million, or about Naveris being worth nothing, the shares are worth materially more; if we are wrong about the Natera appeal, much less. The price assumes a three-to-five-year holding period. Meanwhile, the company has been returning cash through share repurchases ($12.2 million in the first half of 2026). At $2.50 the price is below the excess cash per share, so the excess cash alone covers the price while the business has years to reach breakeven; that is why the margin-of-safety price is $2.50.